Intramyocardial stem cell therapy was safe but lacked significant lasting benefits beyond 6 months in our study cohort with a limited number of patients.
Preoperative left ventricular ejection fraction and time since myocardial infarction may be critical parameters for selection of patients who can benefit most from intramyocardial stem cell treatment during coronary artery bypass grafting.
2011-11-18
Eng.
The Journal of thoracic and cardiovascular surgery
Department of Cardiac Surgery, University of Rostock, Rostock, Germany. gustav.steinhoff [at] med.uni-rostock.de
J Thorac Cardiovasc Surg. 2011 Dec;142(6):1530-9.e3
© Galenicom 1999-2013